Mallinckrodt PLC (MNK)

34.84
0.35 1.00
NYSE : Health Care
Prev Close 34.49
Open 34.45
Day Low/High 34.21 / 35.23
52 Wk Low/High 33.61 / 76.81
Volume 686.17K
Avg Volume 2.52M
Exchange NYSE
Shares Outstanding 97.18M
Market Cap 3.31B
EPS 5.80
P/E Ratio 18.62
Div & Yield N.A. (N.A)

Latest News

The Stock Market Gets Smashed -- Here Are Some Terrible Performers

The Stock Market Gets Smashed -- Here Are Some Terrible Performers

The Dow, Nasdaq and S&P were all in the red Tuesday.

Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice

Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice

-- Infantile hyperbilirubinemia (jaundice) affects approximately 750,000 infants born in the U.S. each year; if unresolved with traditional treatment, can lead to serious medical conditions including permanent neurological injury and death --

Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates

Mallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates

-- Observational Registry With Retrospective Data Collection Designed to Evaluate Premature Versus Term and Near-Term Neonates with Pulmonary Hypertension Receiving Inhaled Nitric Oxide --

Summary Review Of Clinical And Economic Data On H.P. Acthar® Gel (Repository Corticotropin Injection) Published In Advances In Therapy

Summary Review Of Clinical And Economic Data On H.P. Acthar® Gel (Repository Corticotropin Injection) Published In Advances In Therapy

-- Literature review covering decades of data support combination of clinical outcomes, lower use of background medications and reduced post-therapy costs --

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

McCaskill requested that four more drug companies and three drug distributors turn over documents.

Earnings Are Back With a Vengeance: Cramer's 'Mad Money' Recap (Monday 7/24/17)

Earnings Are Back With a Vengeance: Cramer's 'Mad Money' Recap (Monday 7/24/17)

Distortions caused by all these earnings reports coming at once are causing upheaval in the market.

Marriott International, Ionis Pharmaceuticals, NXP Semiconductors: 'Mad Money' Lightning Round

Marriott International, Ionis Pharmaceuticals, NXP Semiconductors: 'Mad Money' Lightning Round

Jim Cramer is bullish on Marriott International, Ionis Pharmaceuticals, and NXP Semiconductors.

Lots of Market Positives Today

But I'm looking for a pullback next week.

Mallinckrodt Phase 3 Terlipressin Trial Achieves Its Enrollment Target Ahead Of Schedule

Mallinckrodt Phase 3 Terlipressin Trial Achieves Its Enrollment Target Ahead Of Schedule

-- Terlipressin CONFIRM Phase 3 Trial Enrolls 75th Patient of 300-Patient Target Enrollment; Marks Halfway Point toward Interim Analysis of Trial Data --

Mallinckrodt Finalizes Previously Announced Agreement With DEA And USAOs

Mallinckrodt Finalizes Previously Announced Agreement With DEA And USAOs

-- Mallinckrodt Reaffirms Industry-Leading Commitment to Ensuring Safe and Appropriate Use of its Specialty Generic Opioid Products --

Mallinckrodt Announces Specialty Brands Investor Briefing

Mallinckrodt Announces Specialty Brands Investor Briefing

-- R&D-Focused Event to Highlight Commercial Portfolio and Growing Pipeline --

Health Economic Data On Burden Of Hepatorenal Syndrome Published In Current Medical Research And Opinion

-- Long Hospital Stays, Frequent Medical Visits and Hospital Readmissions Drive Costs, Payer Burden --

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Mallinckrodt Enrolls First Patient In Phase 2B Trial Of H.P. Acthar® Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS)

--Mallinckrodt's PENNANT Trial to Assess Efficacy and Safety of H.P. Acthar Gel in ALS Patients--

Mallinckrodt Enrolls First Patient In Phase 3 Trial Of StrataGraft® Regenerative Skin Tissue

-- Trial to Assess Efficacy and Safety in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements --

Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop

Wall Street Backs Off of Records After London Terror Attack, Crude Oil Drop

Wall Street wasn't able to extend a record-breaking streak into a third session on Monday after a terror attack in London.

Closing Bell: Stocks Snap Two-Day Winning Streak; Apple to Add Amazon prime to Apple TV

Closing Bell: Stocks Snap Two-Day Winning Streak; Apple to Add Amazon prime to Apple TV

Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.

Stocks Mostly Lower in Cautious Trading, Apple Slips on Downgrade

Stocks Mostly Lower in Cautious Trading, Apple Slips on Downgrade

Stocks are mostly lower on Monday after a terror attack in London over the weekend and following a rare analyst downgrade on Apple shares.

Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication

Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication

Citron attacked Mallinckrodt's partnership with Express Scripts ESRX, liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant.

Mallinckrodt Inquires Into Sale of Generic Drug Unit

Mallinckrodt Inquires Into Sale of Generic Drug Unit

Shares of drug maker Mallinckrodt were falling Wednesday afternoon

Mallinckrodt Explores Sale of Generic Drug Unit

Mallinckrodt Explores Sale of Generic Drug Unit

The unit accounted for about 30% of the company's revenue in the first quarter.

Behind the War Between Health Insurers and Pharmacy Benefit Managers

Behind the War Between Health Insurers and Pharmacy Benefit Managers

More competition could help overcome the suspicion over drug prices that plagues the would-be business partners' dealings.

Mallinckrodt Highlights First Patients In Company-Sponsored Prospective Observational Registry On The Use Of H.P. Acthar® Gel (Repository Corticotropin Injection) Following Acute Multiple Sclerosis Relapse

-- Preliminary Demographic Data on Currently Enrolled Patients to be Presented at the 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers [Poster RT01] --

TheStreet Quant Rating: C- (Hold)